Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 10549-10549
◽
Keyword(s):
2013 ◽
Vol 82
(6)
◽
pp. 923-928
◽
Keyword(s):